Beta Bionics, Inc.
BBNXHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring. The $1.03B market capitalization puts BBNX squarely in small-cap range for its industry. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Market Cap
$1.03B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.87
EPS (TTM)
$-1.64
EPS (Fwd)
$-2.16
ROE
-26.2%
ROA
-16.7%
Cash
$180.5M
Total Debt
$6.5M
Free CF
-$40.3M
52W Change
-8.5%
Annual Financials
Cash vs Debt
Where BBNX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BBNX finished 12.94% above its 150-day moving average ($14.91) and 11.52% above its 200-day moving average ($15.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBNX overbought or oversold?
At the October 20, 2026 close, BBNX's RSI(14) was 26.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $180.5M in cash comfortably exceeding the $6.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$40.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -26.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $179K (2022) to $100.3M (2025), reflecting a 55906% increase over the period.
With cash comfortably exceeding debt, BBNX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Beta Bionics, Inc.'s trajectory.